Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L2 | Q92843 | 3/20 | 0.48 |
| ▸ | BAD | Q92934 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18103048 | 0.88 | KMT2A (0.64) | KMT2AMEN1POLBPKMMAPT | |
| SCHEMBL571618 | 0.71 | PKM (0.66) | KMT2AMEN1POLBPKMMAPT | |
| SCHEMBL6884827 | 0.66 | PTPN1 (0.67) | BCL2L2BADKMT2AMEN1POLB | |
| SCHEMBL6884831 | 0.66 | PTPN1 (0.67) | BCL2L2BADKMT2AMEN1POLB | |
| SCHEMBL18102846 | 0.66 | MEN1 (0.67) | KMT2AMEN1MAPTAKR1B1MITF | |
| SCHEMBL20005602 | 0.66 | KMT2A (0.72) | KMT2AMEN1POLBMAPTCRHBP | |
| SCHEMBL18102931 | 0.66 | KMT2A (0.72) | KMT2AMEN1POLBMAPTCRHBP | |
| SCHEMBL21450932 | 0.65 | PKM (0.63) | KMT2AMEN1PKMAKR1B1 | |
| SCHEMBL18103078 | 0.65 | DUSP22 (0.80) | KMT2AMEN1RAB9ABCL2 | |
| SCHEMBL20006090 | 0.65 | DUSP22 (0.80) | KMT2AMEN1RAB9ABCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | BCL2L2 1616/4885BAD 1165/4885KMT2A 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.